ReviewCureus2017
New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome.
Review in Cureus, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Mexican Plants Involved in Glucose Homeostasis and Body Weight Control: Systematic Review.Nutrients · 2023Pooled it
- The Effects of Probiotic Supplementation on Clinical Symptom, Weight Loss, Glycemic Control, Lipid and Hormonal Profiles, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials.Probiotics and antimicrobial proteins · 2022Pooled it
- Life Modifications and PCOS: Old Story But New Tales.Frontiers in endocrinology · 2022Pooled it
- Acupuncture for hormonal readiness and gut microbiota in obese polycystic ovary syndrome: an open-label, randomized controlled trial.Frontiers in endocrinology · 2024Trial
- Trial
- SMOTE-Based Automated PCOS Prediction Using Lightweight Deep Learning Models.Diagnostics (Basel, Switzerland) · 2024Article
- Androgen-Induced Cardiovascular Risk in Polycystic Ovary Syndrome: The Role of T Lymphocytes.Life (Basel, Switzerland) · 2023Review
- Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome.Biomedicines · 2023Article
- Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment.Journal of ovarian research · 2023Review
- Article
- Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends.Molecules (Basel, Switzerland) · 2022Review
- Quercetin and polycystic ovary syndrome.Frontiers in pharmacology · 2022Review
- Resveratrol ameliorates polycystic ovary syndrome via transzonal projections within oocyte-granulosa cell communication.Theranostics · 2022Article
- Review
- Effect of Trilobatin fromNutrients · 2021Article
- Polycystic Ovary Syndrome: Familiar to Millions?Journal of clinical medicine · 2020Article
- Integrative Management of Metabolic Syndrome in Youth Prescribed Second-Generation Antipsychotics.Medical sciences (Basel, Switzerland) · 2020Review
- Patterns of Bariatric Surgeries Among U.S. Women Diagnosed with Polycystic Ovarian Syndrome.Journal of women's health (2002) · 2020Article
- Polycystic ovary syndrome management: a review of the possible amazing role of berberine.Archives of gynecology and obstetrics · 2020Review
- Use of Acupuncture in Overweight/Obese Women with Polycystic Ovary Syndrome.Medical acupuncture · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a pathophysiological disorder affecting reproductive and metabolic indices. PCOS is commonly associated with a high prevalence of insulin resistance and obesity; this association carries an increased risk of developing metabolic syndrome, type 2 diabetes mellitus (T2DM), and cardiovascular disease. Guidelines recommend lifestyle modification, metformin, hormonal contraceptives (HCs), and bariatric surgery as the main treatment options in obese patients with PCOS. Studies are being conducted to test the efficacy of existing treatment options as well as to discover new therapies. This review focuses on the most recent advances in this regard and highlights new hypotheses and emerging studies to give a picture of the latest therapeutic trends in the treatment of obese patients with PCOS. In this respect, much attention is given to the role of inositols, the mediators of insulin action. A deficiency of d-chiro-inositol containing inositol-phospho-glycans may be the basis of insulin resistance frequently seen in PCOS patients. Moreover, evidence suggests the use of statins in obese women with PCOS, but guidelines call for further research. Adiponectin, quercetin, vitamin D, and anti-obesity drugs have also been studied and seem to have a useful role in the treatment of obesity and metabolic syndrome in PCOS. Many trials have been conducted on the use of non-pharmacological therapies. Therapies including resveratrol, acupuncture, and berberine have favorable effects in overweight PCOS patients. However, more research is needed to reveal the clinical complexity of PCOS and develop more effective treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.